EA201792054A1 - Гетероциклические соединения, применимые в качестве ингибиторов tnf - Google Patents

Гетероциклические соединения, применимые в качестве ингибиторов tnf

Info

Publication number
EA201792054A1
EA201792054A1 EA201792054A EA201792054A EA201792054A1 EA 201792054 A1 EA201792054 A1 EA 201792054A1 EA 201792054 A EA201792054 A EA 201792054A EA 201792054 A EA201792054 A EA 201792054A EA 201792054 A1 EA201792054 A1 EA 201792054A1
Authority
EA
Eurasian Patent Office
Prior art keywords
heterocyclic compounds
tnf inhibitors
compounds
compounds applicable
crr
Prior art date
Application number
EA201792054A
Other languages
English (en)
Russian (ru)
Inventor
Лоренс Р. Марсин
Стивен Т. Вроблески
Т. Г. Мурали Дхар
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA201792054A1 publication Critical patent/EA201792054A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
EA201792054A 2015-03-18 2016-03-17 Гетероциклические соединения, применимые в качестве ингибиторов tnf EA201792054A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134800P 2015-03-18 2015-03-18
PCT/US2016/022742 WO2016149439A1 (en) 2015-03-18 2016-03-17 Heterocyclic compounds useful as inhibitors of tnf

Publications (1)

Publication Number Publication Date
EA201792054A1 true EA201792054A1 (ru) 2018-01-31

Family

ID=55640934

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792054A EA201792054A1 (ru) 2015-03-18 2016-03-17 Гетероциклические соединения, применимые в качестве ингибиторов tnf

Country Status (14)

Country Link
US (1) US10112944B2 (https=)
EP (1) EP3271362B1 (https=)
JP (1) JP6779899B2 (https=)
KR (1) KR102696304B1 (https=)
CN (1) CN107567450B (https=)
AU (1) AU2016233202A1 (https=)
BR (1) BR112017019605A2 (https=)
CA (1) CA2980161A1 (https=)
EA (1) EA201792054A1 (https=)
ES (1) ES2803650T3 (https=)
IL (1) IL254430A0 (https=)
MX (1) MX2017011577A (https=)
SG (1) SG11201707473VA (https=)
WO (1) WO2016149439A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635993B (zh) 2015-03-18 2020-05-22 百时美施贵宝公司 取代的三环杂环化合物
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
EP3288939A1 (en) 2015-04-17 2018-03-07 AbbVie Inc. Tricyclic modulators of tnf signaling
WO2016168633A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
BR112018001980A2 (pt) 2015-08-03 2018-09-18 Bristol Myers Squibb Co compostos cíclicos úteis como moduladores de tnf alfa
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391806A (en) * 1982-07-12 1983-07-05 The Dow Chemical Company Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators
CA2281927C (en) 1997-02-25 2004-01-27 Christopher J. Michejda Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
JPWO2003064422A1 (ja) 2002-01-31 2005-05-26 第一製薬株式会社 イミダゾ[1,2−a]ピリジン誘導体
AU2003298839A1 (en) 2002-12-03 2004-06-23 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
WO2008072682A1 (ja) * 2006-12-15 2008-06-19 Daiichi Sankyo Company, Limited イミダゾ[1,2-b]ピリダジン誘導体
EP2209785A1 (en) 2007-10-05 2010-07-28 S*BIO Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
US9550737B2 (en) 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
MX2015005375A (es) * 2012-11-07 2015-07-21 Hoffmann La Roche Compuestos de triazolo.
WO2014080241A1 (en) * 2012-11-21 2014-05-30 Piramal Enterprises Limited Imidazopyridine compounds and uses thereof
WO2015008611A1 (ja) 2013-07-18 2015-01-22 株式会社 村田製作所 積層型インダクタ素子の製造方法
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US9920052B2 (en) 2013-12-09 2018-03-20 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
RU2685234C1 (ru) 2013-12-09 2019-04-17 Юсб Байофарма Спрл Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
MX388321B (es) 2014-10-06 2025-03-19 Signal Pharm Llc Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
CN107635993B (zh) 2015-03-18 2020-05-22 百时美施贵宝公司 取代的三环杂环化合物

Also Published As

Publication number Publication date
EP3271362A1 (en) 2018-01-24
ES2803650T3 (es) 2021-01-28
US20180072728A1 (en) 2018-03-15
US10112944B2 (en) 2018-10-30
CN107567450A (zh) 2018-01-09
KR20170129192A (ko) 2017-11-24
CN107567450B (zh) 2020-03-13
MX2017011577A (es) 2017-10-26
JP2018512062A (ja) 2018-05-10
SG11201707473VA (en) 2017-10-30
IL254430A0 (en) 2017-11-30
WO2016149439A1 (en) 2016-09-22
BR112017019605A2 (pt) 2018-05-08
JP6779899B2 (ja) 2020-11-04
EP3271362B1 (en) 2020-04-22
KR102696304B1 (ko) 2024-08-16
CA2980161A1 (en) 2016-09-22
AU2016233202A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
EA201792054A1 (ru) Гетероциклические соединения, применимые в качестве ингибиторов tnf
EA201890165A1 (ru) Гетероциклические соединения, применимые в качестве модуляторов tnf-альфа
EA201792025A1 (ru) Трициклические гетероциклические соединения, применимые в качестве ингибиторов tnf
EA201792034A1 (ru) Замещенные трициклические гетероциклические соединения
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA201790740A1 (ru) Индолкарбоксамидные соединения
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
EA202091709A1 (ru) Ингибиторы днк-пк
EA202091708A1 (ru) Ингибиторы днк-пк
EA201992884A2 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA202091484A1 (ru) 4-азаиндольные соединения
EA201790764A1 (ru) Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1
EA202092086A1 (ru) Ингибиторы аргиназы
EA201891091A1 (ru) Соединения ингибитора jak киназы для лечения респираторного заболевания
EA202091777A1 (ru) Аминопирролотриазины в качестве ингибиторов киназы
EA201891103A1 (ru) Композиции для лечения спинальной мышечной атрофии
EA201890421A1 (ru) Циклические соединения, пригодные в качестве модуляторов tnf-альфа
EA201591382A1 (ru) Ингибиторы гистондеметилаз
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ